Compugen (NASDAQ:CGEN) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Compugen Ltd. (NASDAQ:CGEN)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.77 and traded as high as $2.28. Compugen shares last traded at $2.26, with a volume of 205,711 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CGEN. HC Wainwright initiated coverage on shares of Compugen in a research report on Wednesday, January 7th. They issued a “buy” rating and a $4.00 price target for the company. Truist Financial upgraded Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. Finally, Wall Street Zen raised Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $4.00.

Compugen Trading Up 2.7%

The business’s fifty day moving average price is $1.96 and its 200 day moving average price is $1.77. The firm has a market capitalization of $213.68 million, a price-to-earnings ratio of 6.11 and a beta of 2.77.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. The firm had revenue of $67.33 million during the quarter, compared to analysts’ expectations of $14.30 million. Compugen had a net margin of 48.57% and a return on equity of 55.68%. As a group, sell-side analysts forecast that Compugen Ltd. will post -0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compugen

Several institutional investors have recently added to or reduced their stakes in the stock. Bank Hapoalim BM acquired a new stake in Compugen during the 4th quarter worth approximately $37,000. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Compugen in the 4th quarter valued at approximately $38,000. Franklin Resources Inc. acquired a new position in shares of Compugen in the second quarter valued at approximately $56,000. Osaic Holdings Inc. raised its stake in shares of Compugen by 346.0% during the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 34,045 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in shares of Compugen during the fourth quarter worth approximately $84,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.